Corvus To Report Interim Data From Phase 1 Trial Of Soquelitinib For Atopic Dermatitis Today

December 18, 2024 — 03:31 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - Corvus Pharmaceuticals Inc. (CRVS), a clinical-stage biopharmaceutical company, is scheduled to announce interim data from its Phase 1 trial of Soquelitinib in moderate to severe atopic dermatitis today, December 18, 2024.

Soquelitinib (formerly known as CPI-818) is an investigational small molecule drug given orally designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase). ITK is an enzyme that is expressed predominantly in T cells and plays a role in T cell and natural killer (NK) cell immune function.

The phase I trial of Soquelitinib is designed to enroll 64 patients who have failed at least one prior therapy. Four different 28-day dosing regimens of Soquelitinib are evaluated against a placebo group in the study. The endpoints include safety and improvement in the Eczema Area and Severity Index.

Corvus will host a conference call and webcast today December 18, 2024, at 8:00 a.m. ET / 5:00 a.m. PT to discuss the atopic dermatitis trial data.

CRVS closed Tuesday's (Dec.17.2024) trading at $7.39, up 7.10%. In after-hours trading, the stock was up nearly 22% at $9.00.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Corvus To Report Interim Data From Phase 1 Trial Of Soquelitinib For Atopic Dermatitis Today

Tags

Latest Articles